Analysis of Immune Resistance Mechanisms in TNBC:Dual Effects Inside and Outside the Tumor
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Analysis of Immune Resistance Mechanisms in TNBC:Dual Effects Inside and Outside the Tumor
Authors
Keywords
-
Journal
Clinical Breast Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.clbc.2023.10.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer-associated fibroblasts: The chief architect in the tumor microenvironment
- (2023) Mrinmoy Sarkar et al. Frontiers in Cell and Developmental Biology
- A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
- (2023) Clinton Yam et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
- (2022) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
- (2022) Anne Jacobson ONCOLOGIST
- Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment
- (2022) Dimitrios N. Sidiropoulos et al. Cancer Immunology Research
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
- (2022) Javier Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
- (2022) Shijun Ma et al. Nature Communications
- Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
- (2022) Christine Deutschmann et al. BMC CANCER
- Sanyin Formula Enhances the Therapeutic Efficacy of Paclitaxel in Triple-Negative Breast Cancer Metastases through the JAK/STAT3 Pathway in Mice
- (2022) Chunyu Wu et al. Pharmaceuticals
- CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
- (2021) Roberta Zappasodi et al. NATURE
- Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer
- (2021) Feng Jiang et al. Scientific Reports
- Breast cancer
- (2021) Sibylle Loibl et al. LANCET
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
- (2021) Yuqing Zhang et al. JCI Insight
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
- (2020) Jenny H. Lee et al. Nature Communications
- Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer
- (2020) Yann Kieffer et al. Cancer Discovery
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
- (2019) Geoffrey T. Gibney et al. Journal for ImmunoTherapy of Cancer
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- (2018) K. G. Paulson et al. Nature Communications
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells
- (2017) Giada Mondanelli et al. IMMUNITY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Tolerance and immune suppression in the tumor microenvironment
- (2016) Suzanne Ostrand-Rosenberg CELLULAR IMMUNOLOGY
- Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs
- (2016) Fernando Ortiz-Martínez et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- PD-1 Blockade Expands Intratumoral Memory T Cells
- (2016) A. Ribas et al. Cancer Immunology Research
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer
- (2016) Sasha E. Stanton et al. Journal for ImmunoTherapy of Cancer
- A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
- (2015) Shin Foong Ngiow et al. CANCER RESEARCH
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
- (2015) M. Callari et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit
- (2014) Kristen E. Pauken et al. CANCER CELL
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- CD4+ follicular helper T cell infiltration predicts breast cancer survival
- (2013) Chunyan Gu-Trantien et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Migration of Th1 Lymphocytes Is Regulated by CD152 (CTLA-4)-Mediated Signaling via PI3 Kinase-Dependent Akt Activation
- (2012) Karin Knieke et al. PLoS One
- Breast cancer statistics, 2011
- (2011) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started